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ABSTRACT
BACKGROUND: A potential effect of ezerirnibe, a novel cholesterol-absorption
inhibiror, on insulin resistance has been reported in an animal model.
OBJECTIVE: The aim of this study was to evaluate the effects of ezetimibe on
glucose metabolism in patients with type 2 diabetes mellitus (T2DM).
METHODS: Between March and June 2008, outpatients with T2DM who were
being treated at Yokohama Sakae Kyosai Hospital, Yokohama, Japan, were enrolled
in this pilot study if they had not achieved the target lipid levels recommended by
the Japan Atherosclerosis Society Guidelines despite diet and exercise or a statin
therapy for ~3 months. At baseline and at 4 and 12 weeks after open-label treatment
with ezetimibe 10 mg/d, the levels of lipid parameters, fasting plasma glucose (FPG),
glycosylated hemoglobin (HbA l c) ' and high-sensitivity C-reactive protein were mea-
sured. Adverse effects (AEs) were assessedat each study visit by patient interviews and
laboratory testing.
RESULTS: A total of 21 consecutive patients 00 men, 11 women; mean [SDJ
age, 72 [9J years; weight, 63.4 [l0.5J kg; body mass index, 25.5 [3.2J kg/rrr') were
enrolled in this study. The mean (SD) level of LDL-C decreased significantly from
146 (31) to 114 (27) mg/dL (-21 %; P < 0.001) after 12 weeks of treatment with
ezetimibe. The mean level of remnant-like particle cholesterol also decreased signifi-
cantly from 6.5 (3.8) to 4.8 (2.2) mg/dL (-15%; P = 0.03). Treatment with ezetirnibe
was associated with a reduction in FPG level from 127 (31) to 119 (30) mg/dL (P =
0.02), and HbAl c from 6.3% (0.6%) to 6.1 % (0.7%) (P = 0.003). No AEs were ob-
served or reported during the study period.
CONCLUSION: In this small, open-label, uncontrolled, pilot study, ezetimibe was
associated with a significant decrease in lipid parameters and improvement in glucose
metabolism in these patients with T2DM. (Curr Ther Res Clin Exp. 2010;71:252-
258) © 2010 Excerpta Medica Inc.
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INTRODUCTION
Ezetimibe is a cholesterol-absorption inhibitor that strongly inhibits the absorption
of biliary and dietary cholesterol at the brush border of the intestine without affecting the
absorption of fat-soluble vitamins.l-' Ezetimibe appears to inhibit cholesterol absorption
by binding with the cholesterol transporter, Niemann-Pick Cl-like 1 (NPCIL1) protein.>
Although the main effect of ezetimibe is to decrease total cholesterol (TC) and LDL-C
levels, several studies have found that ezetimibe is also associated with decreased
triglyceride (TG) levels.4,5
A 2007 study reported a potential effect of ezetimibe on insulin resistance and
liver steatosis in an animal model," and ezetimibe was found to improve postprandial
hyperlipidemia by reducing free fatty acid (FFA) absorption," Based on these consid-
erations, we hypothesized that ezetimibe would improve glucose metabolism in patients
with type 2 diabetes mellitus (T2DM). This hypothesis was tested prospectively in
patients with T2DM and dyslipidemia.
PATIENTS AND METHODS
PATIENTS
Between March and June 2008, outpatients with T2DM who were being treated
at the Yokohama Sakae Kyosai Hospital, Yokohama, Japan, were enrolled in this pilot
study if they had not achieved the target lipid levels (LDL-C, 2':120 mg/dL or
2':100 mg/dL in patients with coronary artery disease) recommended by the Japan
Atherosclerosis Society Guidelines'' despite diet and exercise or a statin therapy for
2':3 months. Patients were excluded from the study for the following reasons: treat-
ment with nonstatin lipid-lowering drugs (eg, fibrates, nicotinic acid, cholestyramine,
probucol); dyslipidemia associated with hypothyroidism, nephrotic syndrome, gall-
bladder obstruction, biliary disease, pancreatitis, or immunologic abnormalities such
as collagen diseases; dyslipidemia induced by steroids or other drugs; positive viral
hepatitis B or C; alcoholism or heavy alcohol intake; T2DM treated with insulin or
that was poorly controlled (glycosylated hemoglobin (HbA 1c1 >8.0%); and any
other reason for which the patient was considered inappropriate for this study by
the attending physician.
STUDY DESIGN
Written informed consent was obtained from all patients, and the Ethics Committee
of our hospital approved the study protocol.
Ezetimibe" 10 mg/d was administered to all patients for 12 weeks. The patients
were required to visit the hospital at 4 and 12 weeks after enrollment. The lipid
parameters, fasting plasma glucose (FPG), HbA1c' and high-sensitivity C-reactive
protein (hs-CRP) were measured at baseline, and at 4 and 12 weeks. Adverse effects
(AEs) were assessed at each study visit by patient interviews and laboratory
testing.
*Trademark: Zetia® (Bayer Yakuhin Ltd., Osaka, Japan).
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T2DM was diagnosed if the FPG level was ~126 mg/dL, a random plasma glu-
cose level was ~200 mg/dL, the HbA 1c level was ~6.5%, or in case of treatment with
either oral hypoglycemic agents or insulin.? During the study period, there were no
lifestyle changes, nonstudy antidyslipidemic agents were prohibited, and antihyper-
tensive and antidiabetic treatments used at enrollment were continued without dose
modifications.
LABORATORY DETERMINATIONS
Blood samples were obtained after overnight fasting for 12 hours. The HbA1c level
was measured by HPLC (Adams A1c HA-8160; Arkray Inc., Kyoto, Japan) and the
plasma glucose level was measured using the glucose oxidation method (chemical
reagent and Glucose AUTO and STAT GA-1160 analyzer; Arkray Inc.). Serum levels
ofTC, LDL-C, and HDL-C were measured using commercial enzymatic kits (Kyowa
Medex, Tokyo, Japan). TG was measured enzymatically (Kyowa Medex). Serum levels
of apolipoproteins (apos), remnant-like particle cholesterol (RLP-C), and hs-CRP were
measured at a central laboratory (SRL Inc., Tokyo, Japan). The serum level of RLP-C
was measured using an immune-separation technique.
STATISTICAL ANALYSIS
Statistical analyses were performed using Sratview 5.0 software (SAS Institute Inc.,
Cary, North Carolina). Results are expressed as mean (SD). The Wilcoxon signed rank
test was used to compare the data before and after ezerimibe treatment. The statistical
significance level was set at P < 0.05. Corrections for multiple comparisons and a
sample-size calculation were not performed.
RESULTS
A total of 21 consecutive patients (l0 men, 11 women; mean [SD} age, 72 [9} years;
weight, 63.4 [l0.5} kg; body mass index, 25.5 [3.2} kg/rrr') were enrolled in this
study. The baseline characteristics of the subjects are shown in Table I. Seven patients
<33%) had received antidiabetic drugs and the other 14 patients (67%) were being
treated with diet and exercise therapy alone. Fifteen patients (71%) were already be-
ing treated with statins.
The effects of ezerimibe administration on lipid parameters, FPG, HbA 1c and
hs-CRP are shown in Table II. After 12 weeks of treatment with ezetirnibe, the
mean (SD) levels of TC, LDL-C, apo B, and RLP-C decreased significantly from
223 (35) to 183 (29) mg/dL (-17%; P < 0.001), 146 (31) to 114 (27) mg/dL
(-21%; P < 0.001), 114 (20) to 94 (17) mg/dL (-16%; P < 0.001), and 6.5 (3.8)
to 4.8 (2.2) mg/dL (-15%; P = 0.03), respectively. The mean level ofTG decreased
from 164 (81) to 144 (52) mg/dL, but it was not statistically significant. The
HDL-C level did not show a significant change. The mean levels of FPG and
HbA1c decreased significantly from 127 (31) to 119 (30) mg/dL (P = 0.02) and
6.3% (0.6%) to 6.1% (0.7%) (P = 0.003), respectively. The mean level of
hs-CRP decreased from 2.3 (3.4) to 0.5 (0.8) mg/L, but did not reach statistical
significance.
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Table I. Baseline characteristics of sUbjects (N =21). Data are
mean (SD) unless otherwise indicated.
Variable
Age, y
Sex, male/female
Height, cm
Weight, kg
BMI, kg/m2
TC, rng/dt,
LDL-C, mg/dl,
HDL-C, mg/dl,
TG, mg/dl,
RLP-C, mg/dl,
FPG, rng/dl,
Smoking, no. (%)
History of CAD, no. (%)
Hypertension, no. (%)
Statins, no. (%)
Antidiabetic drugs, no. (%)
Sulfonylurea
Pioglitazone
Biguanide + u-GI
Sulfonylurea + biguanide + u-GI
Value
72 (9)
10/11
157.4 (10.2)
63.4 (10.5)
25.5 (3.2)
223 (35)
146 (31)
58 (12)
164 (81)
6.5 (3.8)
127 (31)
o
13 (62)
15 (71)
15 (71)
7 (33)
4 (57)
1 (14)
1 (14)
1 (14)
8MI = body mass index; TC = total cholesterol; TG = triglycerides; RLP-C =
remnant-like particle cholesterol; FPG = fasting plasma glucose; CAD =
coronary artery disease; a-GI = a-glucosidase inhibitor.
No AEs, including the occurrence of clinical symptoms or changes in the bio-
chemical parameters, were observed or reported during the study period.
DISCUSSION
Although the main effect of ezetimibe is to decrease the TC and LOL-C levels, a sig-
nificant decrease in RLP-C was observed in the present study. The percentage changes
in TC, LOL-C, apo B, and RLP-C after 12 weeks of treatment with ezetimibe were
-17%, -21 %, -16%, and -15%, respectively. Recently, we reported the results of a
prospective, open-label, uncontrolled study to evaluate the effect of ezetimibe on
RLP-C in patients with dyslipidemia that found a 21% decrease in the mean RLP-C
level (P < 0.001).10 The same result was observed in the present study in these pa-
tients with T20M.
Although mean (SO) HbA l c decreased significantly from 6.3% (0.6%) to 6.1 %
(0.7%), the mechanism by which ezetimibe treatment improves glucose metabolism
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Table II. Effects of ezetimibe on lipid parameters, highly selective C-reactive protein
(hs-CRP), fasting plasma glucose (FPG), and glycosylated hemoglobin (HbAl e) .
Data are mean (SO) mgjdL, unless otherwise indicated.
Parameter Baseline 4 Weeks 12 Weeks
TC 223 (35) 187 (30)* 183 (29)*
LDL-C 146 (31) 113 (26)* 114 (27)*
HDL-C 58 (12) 61 (14) 56 (10)
TG 164 (81) 134 (55) 144 (52)
RLP-C 6.5 (3.8) 4.8 (2.1)t 4.8 (2.2)t
Ape AI 141 (27) 145 (25) 141 (25)
Ape B 114 (20) 94 (17)* 94 (17)*
Ape E 4.3 (1.0) 4.0 (O.8)t 4.1 (1.0)
hs-CRP, mg/L 2.3 (3.4) 0.9 (2.0) 0.5 (0.8)
FPG 127 (31) 117 (29) 119 (30)t
HbA1c' % 6.3 (0.6) 6.2 (O.6)t 6.1 (0.7)1'
TC = total cholesterol; TG triglycerides; RLP-C remnant-like particle cholesterol; Apo =
apolipoprotein.
»P < 0.001 versus baseline.
t p = 0.03 versus baseline.
f P = 0.02 versus baseline.
is still not fully understood. Physiologic elevation of the plasma FFA level causes
muscle and hepatic insulin resistance, resulting in increased rates of endogenous
glucose production related to the prevailing degree of hyperinsulinernia, as well as
decreased glucose uptake by muscle. 11 This can lead to an increase in the plasma
glucose concentration and eventually to T2DM. The sustained reduction of FFA in
the plasma is associated with improved oral glucose tolerance and enhanced periph-
eral and hepatic insulin sensitivity. 12 Deushi et al6 reported that ezetimibe was as-
sociated with reduced FFA (-31 %) in an experimental study in rats. Masuda et all
also reported the results of a prospective, open-label, uncontrolled study in which
ezetirnibe was associated with reduced FFA levels in the oral fat loading test
(P = 0.004). This reduction in FFA is the first reason why ezetimibe might improve
glucose metabolism. Because ezetirnibe inhibits direct uptake of cholesterol from
the intestinal lumen, less cholesterol is transported in chylornicrons, implying a
reduction in the cholesterol reaching the liver in chylomicron remnants.vl'' Ezeri-
mibe reduces hepatic cholesterol by inhibiting NPC 1Ll activity not only in the
intestine, but also in the liver.l" It seems possible that these effects of ezetimibe
alleviate hepatic steatosis'v'? and lead to improvement of insulin resistance.? This
reduction in hepatic cholesterol is the second reason why ezerirnibe might improve
glucose metabolism.
No AEs were observed during the study period. The results of the Simvastatin and
Ezetimibe in Aortic Stenosis (SEAS) trial,16 a multicenter, prospective, randomized,
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double-blind study to evaluate the effect of simvastatin plus ezetimibe on aortic stenosis,
has led to the hypothesis that adding ezetimibe to statin therapy to achieve stronger
LDL-C reduction may increase the incidence of cancer (l05 vs 70; P = 0.01). How-
ever, long-term statin treatment has not been associated with an increased incidence
of, or death from, cancer.l? Peto et al 18 found that the available results of 3 trials do
not provide credible evidence of any AEs of ezetimibe associated with the rates of
cancer. Because ezetirnibe has been studied less extensively than statins, further stud-
ies are necessary to assess the cancer risk.
STUDY LIMITATIONS
This was a small, open-label, uncontrolled, pilot study and the observation period
was only 12 weeks. Additionally, we evaluated only a few glycemic parameters and
most patients were already on starin therapy. Therefore, further, adequately powered,
randomized, controlled trials are necessary to confirm the effects of ezetimibe on glucose
metabolism.
CONCLUSION
In this small, open-label, uncontrolled, pilot study, ezetimibe was associated with
significantly decreased lipid parameters and improved glucose metabolism in these
patients with T2DM.
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